Table 2.
Adverse events related to durvalumab in the 2-weekly and 4-weekly patient cohorts.
| Event Type | 2-weekly durvalumab (n = 40 patients) |
4-weekly durvalumab (n = 14 patients) |
||
|---|---|---|---|---|
| Any grade | Grade 3 or 4 | Any grade | Grade 3 or 4 | |
| Any event | 88 (34 patients) | 6 (6 patients) | 48 (13 patients) | 1 (1 patient) |
| Cough | 9 (10 %) | 0 | 1 (2%) | 0 |
| Pneumonitis | 4 (4.5 %) | 3 (3%) | 3 (6%) | 0 |
| Fatigue | 10 (11 %) | 0 | 2 (4%) | 0 |
| Dyspnoea | 8 (9%) | 0 | 3 (6%) | 0 |
| Diarrhoea | 1 (1%) | 1 (1%) | 0 | 0 |
| Pyrexia | 0 | 0 | 2 (4%) | 0 |
| Nausea | 0 | 0 | 2 (4%) | 0 |
| Pneumonia | 1 (1%) | 0 | 1 (2%) | 0 |
| Arthralgia | 3 (3%) | 0 | 1 (2%) | 0 |
| Upper respiratory tract infection | 1 (1%) | 0 | 1 (2%) | 0 |
| Pruritus | 3 (3%) | 0 | 0 | 0 |
| Rash | 8 (9%) | 2 (2%) | 4 (8%) | 0 |
| Constipation | 1 (1%) | 0 | 1 (2%) | 0 |
| Backpain | 3 (3%) | 0 | 0 | 0 |
| Musculoskeletal pain | 4 (4.5 %) | 0 | 1 (2%) | 0 |
| Anaemia | 0 | 0 | 1 (2%) | 0 |
| Myositis | 0 | 0 | 1 (2%) | 1 (2%) |
| Peripheral sensory neuropathy | 1 (1%) | 0 | 1 (2%) | 0 |
| Limb oedema | 1 (1%) | 0 | 0 | 0 |
| Dry skin | 2 (2%) | 0 | 3 (6%) | 0 |
| Dizziness | 0 | 0 | 4 (8%) | 0 |
| Blurred vision | 0 | 0 | 1 (2%) | 0 |
| Agitation (mood disturbance) | 2 (2%) | 0 | 0 | 0 |
| Weight loss | 1 (1%) | 0 | 0 | 0 |
| Abdominal pain | 2 (2%) | 0 | 0 | 0 |
| Oropharyngeal pain | 2 (2%) | 0 | 1 (2%) | 0 |
| Oral thrush | 4 (4.5 %) | 0 | 0 | 0 |
| Dry mouth | 1 (1%) | 0 | 0 | 0 |
| Hypothyroidism | 10 (11 %) | 0 | 8 (17 %) | 0 |
| Hyperthyroidism | 6 (7%) | 0 | 1 (2%) | 0 |
| Hyperglycaemia | 0 | 0 | 2 (4%) | 0 |
| Lymphopaenia | 0 | 0 | 2 (4%) | 0 |
| ALT rise | 0 | 0 | 1 (2%) | 0 |
ALT: alanine aminotransferase.
40 patients were included in the 2-weekly cohort and 14 of these patients switched to 4-weekly treatment during the COVID-19 pandemic. Percentages refer to the % of each adverse event in relation to the total number of adverse events.